Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
39.8 GBX | +1.02% | +1.79% | -37.03% |
Mar. 27 | Jefferies Downgrades Life Science REIT to Hold from Buy, Cuts PT | MT |
Mar. 27 | Sorted renews M&S deal; Tribe completes drill build | AN |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 354.4 | 253 | 221.2 | 139.3 | - | - |
Enterprise Value (EV) 1 | 354.4 | 207.4 | 314.8 | 269.7 | 285.9 | 295.4 |
P/E ratio | 46 x | -9.15 x | -10.2 x | 12.8 x | 9.71 x | 6.75 x |
Yield | - | 5.53% | 6.33% | 6.91% | 7.44% | 7.16% |
Capitalization / Revenue | - | 19.5 x | 16 x | 7.22 x | 5.84 x | 5.5 x |
EV / Revenue | - | 16 x | 22.8 x | 14 x | 12 x | 11.7 x |
EV / EBITDA | - | 93.6 x | 36.7 x | 21.4 x | 17.3 x | 15.9 x |
EV / FCF | - | - | -19.2 x | -135 x | 286 x | 295 x |
FCF Yield | - | - | -5.22% | -0.74% | 0.35% | 0.34% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 350,000 | 350,000 | 350,000 | 350,000 | - | - |
Reference price 2 | 1.012 | 0.7230 | 0.6320 | 0.3980 | 0.3980 | 0.3980 |
Announcement Date | 5/23/22 | 3/27/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | 12.97 | 13.8 | 19.3 | 23.87 | 25.35 |
EBITDA 1 | - | 2.217 | 8.576 | 12.6 | 16.5 | 18.6 |
EBIT | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -27.47 | -21.85 | 10.8 | 14.4 | 20.5 |
Net income 1 | 7.741 | -27.61 | -21.71 | 10.8 | 14.4 | 20.5 |
Net margin | - | -212.92% | -157.29% | 55.96% | 60.34% | 80.87% |
EPS 2 | 0.0220 | -0.0790 | -0.0620 | 0.0310 | 0.0410 | 0.0590 |
Free Cash Flow 1 | - | - | -16.42 | -2 | 1 | 1 |
FCF margin | - | - | -118.98% | -10.36% | 4.19% | 3.94% |
FCF Conversion (EBITDA) | - | - | - | - | 6.06% | 5.38% |
FCF Conversion (Net income) | - | - | - | - | 6.94% | 4.88% |
Dividend per Share 2 | - | 0.0400 | 0.0400 | 0.0275 | 0.0296 | 0.0285 |
Announcement Date | 5/23/22 | 3/27/23 | 3/26/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | 93.6 | 130 | 147 | 156 |
Net Cash position 1 | - | 45.6 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | 10.91 x | 10.35 x | 8.885 x | 8.392 x |
Free Cash Flow 1 | - | - | -16.4 | -2 | 1 | 1 |
ROE (net income / shareholders' equity) | - | - | 2.22% | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | - | 24 | 33 | 22 | 10 |
Capex / Sales | - | - | 174.16% | 170.98% | 92.18% | 39.45% |
Announcement Date | 5/23/22 | 3/27/23 | 3/26/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.03% | 175M | |
+3.95% | 27.38B | |
+8.39% | 24.98B | |
+1.74% | 21.07B | |
+2.09% | 16.07B | |
+0.79% | 15.54B | |
-13.32% | 14.62B | |
+0.03% | 13.1B | |
+0.63% | 12.59B | |
-10.39% | 11.81B |
- Stock Market
- Equities
- LABS Stock
- Financials Life Science REIT plc